Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H26N2O6S2 |
Molecular Weight | 406.517 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)CCCC[C@@H]1CCSS1)C(O)=O
InChI
InChIKey=MQXRTCVZPIHBLD-TUAOUCFPSA-N
InChI=1S/C16H26N2O6S2/c1-10(16(23)24)17-15(22)12(6-7-14(20)21)18-13(19)5-3-2-4-11-8-9-25-26-11/h10-12H,2-9H2,1H3,(H,17,22)(H,18,19)(H,20,21)(H,23,24)/t10-,11+,12-/m0/s1
CMX-2043 is a is an α-lipoic acid analog developed by Ischemix LLC for reduction of cellular injury and organ damage due to ischemia-reperfusion injury (IRI). CMX-2043 was more effective than lipoic acid in antioxidant effect, activation of insulin receptor kinase, soluble tyrosine kinase, and Akt phosphorylation, and activated insulin-like growth factor 1 as effectively as lipoic acid. In a rat model of cardiac ischemia-reperfusion injury, treatment with CMX-2043 reduced myocardial IRI as measured by the myocardial infarction/area at risk ratio, and reduced the incidence of arrhythmia. In a 360-patient Phase 2 trial, CMX-2043 demonstrated safety but did not meet pre-specified endpoints regarding prevention of contrast-induced acute kidney injury or cardiac injury in cardiac catheterization lab subjects, and no further development of the drug was reported.
Originator
Approval Year
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
910627-26-8
Created by
admin on Sat Dec 16 08:37:53 GMT 2023 , Edited by admin on Sat Dec 16 08:37:53 GMT 2023
|
PRIMARY | |||
|
49802864
Created by
admin on Sat Dec 16 08:37:53 GMT 2023 , Edited by admin on Sat Dec 16 08:37:53 GMT 2023
|
PRIMARY | |||
|
DB12795
Created by
admin on Sat Dec 16 08:37:53 GMT 2023 , Edited by admin on Sat Dec 16 08:37:53 GMT 2023
|
PRIMARY | |||
|
83V80O4XY1
Created by
admin on Sat Dec 16 08:37:53 GMT 2023 , Edited by admin on Sat Dec 16 08:37:53 GMT 2023
|
PRIMARY |
ACTIVE MOIETY